AMPH Live signaler | Maksimer profitt med Getagraph.com

SELG 109285 min ago

@ $55.32

Utstedt: 13 feb 2024 @ 17:06

Avkastning: -25.61%

Forrige signal: feb 13 - 15:30

Forrige signal: Kjøp

Avkastning: 0.69 %

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 15:30):

Stats
Dagens volum	9 857.00
Gjennomsnittsvolum	419 558
Markedsverdi	2.01B
EPS	$0 ( 2024-02-27 )
Neste inntjeningsdato	( $0 ) 2024-05-07
Last Dividend	$0.300 ( 2010-06-11 )
Next Dividend	$0 ( N/A )
P/E	15.83
ATR14	$0.0220 (0.05%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Petersen Floyd F.	Sell	500	Common Stock
2024-03-15	Zhang Jack Y.	Buy	722 046	Common Stock
2024-03-15	Zhang Jack Y.	Sell	408 721	Common Stock
2024-03-17	Zhang Jack Y.	Sell	15 768	Common Stock
2024-03-15	Zhang Jack Y.	Buy	310 930	Common Stock

INSIDER POWER
-2.74
Last 100 transactions
Buy: 1 574 905 \| Sell: 1 727 474

Volum Korrelasjon

Lang: -0.41 (neutral)

Kort: -0.83 (strong negative)

Signal:(42.712) Neutral

Amphastar Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
LMNR	0.96
PDFS	0.955
RCEL	0.953
GEOS	0.953
ALTR	0.951
VTYX	0.951
ERII	0.95
SLMBP	0.95
PANL	0.946
ANSS	0.945

10 Mest negative korrelasjoner
CSSEP	-0.95
NAKD	-0.95
ALXO	-0.95
MICS	-0.95
BLUE	-0.946
CBNK	-0.944
PMVP	-0.943
CMLS	-0.94
BWB	-0.94
FGBI	-0.939

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Amphastar Pharmaceuticals Korrelasjon - Valuta/Råvare

-0.62
( weak negative )

-0.37
( neutral )

0.00
( neutral )

-0.31
( neutral )

0.27
( neutral )

0.48
( neutral )

Amphastar Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$644.40M
Bruttogevinst:	$343.97M (53.38 %)
EPS:	$2.85

FY	2023
Omsetning:	$644.40M
Bruttogevinst:	$343.97M (53.38 %)
EPS:	$2.85

FY	2022
Omsetning:	$498.99M
Bruttogevinst:	$248.86M (49.87 %)
EPS:	$1.880

FY	2021
Omsetning:	$437.77M
Bruttogevinst:	$199.74M (45.63 %)
EPS:	$1.350

Financial Reports:

No articles found.

Amphastar Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Amphastar Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.09 - Potential for dividend initiation, but uncertain (18.12%)

Information

First Dividend	$0.300	2009-06-11
Last Dividend	$0.300	2010-06-11
Next Dividend	$0	N/A
Payout Date	2010-06-30
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.600	--
Avg. Dividend % Per Year	0.00%	--
Score	2.66	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.09
Div. Directional Score	7.14	--

Next Divdend (Est)
(2025-03-28)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

2.66

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.213	1.500	5.73	8.60	[0 - 0.5]
returnOnAssetsTTM	0.0909	1.200	6.97	8.36	[0 - 0.3]
returnOnEquityTTM	0.232	1.500	8.53	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.17	0.800	4.14	3.31	[1 - 3]
quickRatioTTM	1.660	0.800	4.94	3.95	[0.8 - 2.5]
cashRatioTTM	0.641	1.500	7.55	10.00	[0.2 - 2]
debtRatioTTM	0.392	-1.500	3.46	-5.19	[0 - 0.6]
interestCoverageTTM	9.50	1.000	7.59	7.59	[3 - 30]
operatingCashFlowPerShareTTM	3.83	2.00	8.72	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.03	2.00	8.48	10.00	[0 - 20]
debtEquityRatioTTM	0.928	-1.500	6.29	-9.43	[0 - 2.5]
grossProfitMarginTTM	0.541	1.000	4.32	4.32	[0.2 - 0.8]
operatingProfitMarginTTM	0.294	1.000	6.12	6.12	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.309	1.000	9.39	9.39	[0.2 - 2]
assetTurnoverTTM	0.426	0.800	-0.494	-0.395	[0.5 - 2]
Total Score				10.19

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	14.33	1.000	8.65	0	[1 - 100]
returnOnEquityTTM	0.232	2.50	9.06	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.03	2.00	8.99	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.83	2.00	8.72	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.191	1.500	-2.06	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.285	1.000	5.38	0	[0.1 - 0.5]
Total Score				4.09

Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.